2015 Towards an HIV Cure Symposium
18 & 19 July 2015

Day 2

Oral Abstract Session 3: Novel Strategies to Identify and Quantify Virus Persistence in vivo (Biomarkers)


Invited Speaker: Engineering T cells to functionally cure HIV-1 infection
James Riley
Perelman School of Medicine, University of Pennsylvania, United States


OA3-1: Immunological Markers associated with HIV Persistence During ART Identified by Iterated Conditional Random Forests Analysis
Remi Fromentin
CRCHUM, Canada


OA3-2: Patient-derived defective HIV-1 proviruses containing large internal deletions can be transcribed and translated
Ross Pollack
The Johns Hopkins University School of Medicine, United States


OA3-3: Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4+ T-cell count at 96 weeks ART
Alexander Pasternak
Academic Medical Center of the University of Amsterdam, Netherlands


OA3-4: Distinct HIV Genetic Populations in Effector Memory T-cells after Prolonged Therapy
Eunok Lee
Westmead Millennium Institute for Medical Research, University of Sydney, Australia


OA3-5 LB: Investigating the Role of the Immune Checkpoint Receptor TIGIT in T cells during HIV Disease Progression and as a Target for Immune Restoration
Glen Chew
University of Hawaii, United States


Oral Abstract Session 4: Immunology and Persistence


Invited Speaker: CHERUB: Collaboration in HIV Eradication in the UK; Predictors of PTC and Viral Reactivation Strategies
Sarah Fidler
Imperial College London, United Kingdom


OA4-1: Trancriptomics and Metabolomics identify inflammatory profiles that segregate subjects with High and Low inducible HIV reservoir
Khader Ghneim
Case Western Reserve University, United States


OA4-2: Virologic and immunologic correlates of viral control post-ART interruption in SIV-infected rhesus macaques
Mirko Paiardini
Emory University, United States


OA4-3: Zinc Finger Nuclease Gene Editing for Functional Cure in a Nonhuman Primate Model of HIV/AIDS
Christopher Peterson
Fred Hutchinson Cancer Research Center, United States


OA4-4 LB: HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected child
Asier Saez-Cirion
Institut Pasteur, France


OA4-5 LB: A Novel Therapeutic HIV-1 Vaccine Trial in Patients under HAART
Frank Tung
GeneCure Biotechnologies, United States


Roundtable: Key Partnerships: Community & Private Sector



Chair: Sharon Lewin
Doherty Institute, The University of Melbourne, Australia

Panelists:
David Margolis
University of North Carolina at Chapel Hill, United States


Andrew Spaltenstein
GlaxoSmithKline, United States


Lynda Dee
CARE CAB; AIDS Action Baltimore, United States


Erik Iverson
Infectious Diseases Research Institute, United States


Veronica Miller
UC Berkeley; Forum for HIV Collaborative Research, United States



Closing  Session


Closing Lecture:  HBV Cure: Possible Lessons for HIV-AIDS
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia


IAS/ANRS HIV Cure Young Investigator Award Ceremony

 

With the support of: